News

Updated HIV, HCV, HBV blood product screening test approved


 

References

An updated version of a blood screening assay that detects human immunodeficiency virus type 1 (HIV-1), hepatitis C virus (HCV), and hepatitis B virus (HBV) in donated blood has been approved by the Food and Drug Administration, the manufacturer, Roche, recently announced.

In a Jan. 9 press release, the company said that its “cobas TaqScreen MPX Test, v2.0” was approved for use “in the detection and identification” of HIV, HCV, and HBV in donations of human whole blood and blood components including source plasma. The test “provides increased sensitivity and is the only FDA approved test to simultaneously detect and identify the most critical viral targets in one simple, ready-to-use assay.,“ according to the statement.

emechcatie@frontlinemedcom.com

Recommended Reading

Clinical factors associated with IBD can increase risk of CMV disease
MDedge Family Medicine
Sofosbuvir and ribavirin critical to preventing posttransplantation HCV recurrence
MDedge Family Medicine
FDA approves IV antibacterial for complicated UTIs, abdominal infections
MDedge Family Medicine
Gilead’s hepatitis C drugs to be sold exclusively at CVS
MDedge Family Medicine
Microbiota organization influences colorectal cancers
MDedge Family Medicine
Outcomes of stage III colon cancer appear better for aspirin, COX-2 inhibitor users
MDedge Family Medicine
Analysis: Push for expanded hepatitis C screening appears premature
MDedge Family Medicine
FDA approves vagal blocking device for obesity
MDedge Family Medicine
Aetna customers to receive discount on Gilead’s hepatitis C treatment
MDedge Family Medicine
Vitamin D appears protective in patients with metastatic colorectal cancer
MDedge Family Medicine